LactoStop Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Financing Rounds
-
2
LactoStop General Information
Description
Developer of anti-lactose intolerant medicine intended to enable people with a lactose intolerance to enjoy milk products. The company's anti-lactose intolerant medicine replaces the body-specific lactase lacking in lactose-intolerant individuals, enabling patients to avail high-quality natural products, food supplements and medical products.
Contact Information
Website
www.lactostop.de
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Parent Company
Dermapharm
Primary Office
- Am Haag 14
- 82166 Grafelfing
- Germany
+49 089 000000000
LactoStop Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
LactoStop Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
LactoStop Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Clemens Fischer Ph.D | Chief Executive Officer |
LactoStop Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|